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Rotational-echo double-resonance (REDOR) NMR is a powerful and versatile solid-state NMR measure-
ment that has been recruited to elucidate drug modes of action and to drive the design of new therapeu-
tics. REDOR has been implemented to examine composition, structure, and dynamics in diverse
macromolecular and whole-cell systems, including taxol-bound microtubules, enzyme–cofactor–inhibi-
tor ternary complexes, and antibiotic–whole-cell complexes. The REDOR approach involves the inte-
grated design of speciﬁc isotopic labeling strategies and the selection of appropriate REDOR
experiments. By way of example, this digest illustrates the versatility of the REDOR approach, with an
emphasis on the practical considerations of experimental design and data interpretation.
 2014 The Author. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.The translation of discoveries at the bench into therapies to pre- ten unique role in elucidating drug modes of action and in driving
vent and treat human disease and to improve overall health is a
grand challenge and ultimate goal of many basic science research
programs and of much larger laboratories and companies that ulti-
mately develop drugs and bring them to the clinic. Drug design and
discovery efforts are enormously interdisciplinary endeavors,
involving small and large molecules, biological targets, and the
complexities of human physiology and drug pharmacology. The
notion of ‘the magic bullet,’ popularized by Dr. Ehrlich, illustra-
tively emphasizes the ultimate goal of identifying a highly selec-
tive therapeutic strategy to exert its action with no side effects
or toxicity. While there are tremendous opportunities and active
research in the areas of protein therapy, immunotherapy, and gene
therapy, most current therapies employ small-molecule drugs to
inﬂuence biological and biochemical phenomena in the host.
Determining the bio-active bound conformations of drugs and
mapping their interactions with their targets with high resolution
are crucial to understanding the molecular and chemical basis for
drug modes of action.
Solid-state NMR has emerged as a powerful tool to examine
biologically relevant drug-bound complexes of systems that pose
a challenge to analysis by conventional methods. Rotational-echo
double-resonance (REDOR) NMR,1 in particular, has played an of-the design of new therapeutic candidates.2–4 Since its introduction
in 1989, REDOR has been implemented to examine composition,
structure, and dynamics in diverse biological macromolecular
and whole-cell systems including enzyme–cofactor–inhibitor ter-
nary complexes, protein–protein complexes, lipid-embedded
membrane proteins, bacteria–antibiotic complexes, and intact
leaves.2–5 REDOR measurements can be implemented to determine
the strength of dipolar couplings, and hence precise distances, be-
tween heteronuclei and can also be used as a spectroscopic ﬁlter.
The REDOR approach is powerful, versatile, and applicable to
many systems, yet there is no set protocol and is best appreciated
by way of example. This digest will provide an introduction to the
REDOR measurement and will highlight three examples that
implement REDOR in distinct ways to deliver insights in drug de-
sign and discovery. Emphasis will be placed on the practical con-
siderations of the examples presented, rather than discussing the
in depth biological implications of the discoveries that resulted
from the REDOR studies. The hope is to describe and illustrate
key parameters and considerations in designing and performing
REDOR measurements for drug design and discovery problem-
solving efforts. The speciﬁc examples have been selected from
the author’s current and former laboratories, although REDOR is
a robust experiment and has been performed and utilized in crea-
tive and important ways in laboratories around the world.
REDOR access to dipolar couplings: Rotational-echo double-
resonance (REDOR) provides a direct measure of short and
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heteronuclei.1 The dipolar coupling between two spins harbors
contributions from the internuclear distance and the orientation
of the internuclear vector with respect to the applied magnetic
ﬁeld,6 allowing REDOR to function as a spectroscopic ruler and pro-
tractor. A brief primer on the REDOR experiment follows. More
complete descriptions of the evolution of the dipolar coupling are
beyond the scope of this digest and are available in the references
cited here.3,7,8
The dipole–dipole coupling between heteronuclei within a
magnetic ﬁeld is dependent upon both spatial and spin coordi-
nates, as described by the truncated dipolar Hamiltonian below (1).
HD ¼ xDIZSZ; xD ¼ 3cos
2h 1
2
 D; D ¼ l0c1c2h
8p2r3
ð1Þ
The angle, h, is the angle between the I–S internuclear vector
and the applied magnetic ﬁeld; c1 and c2 are the gyromagnetic ra-
tios of the I and S nuclei; ⁄ is the reduced Planck constant; and r is
the internuclear vector between the two spins. See Figure 2 for val-
ues of constants. Magic-angle spinning, which is performed to
yield high-resolution NMR spectra, averages over the spatial coor-
dinates and suppresses the dipolar interaction in a coherent man-
ner.9 In solution-state NMR, molecular tumbling averages the
dipolar coupling in a noncoherent manner. Thus, in solution
NMR, unless strategies are used to prevent this averaging (such
as using aligned media or viscous solvents),10 the dipolar couplings
are averaged and cannot be accessed. Magic-angle spinning aver-
ages the dipolar couplings in a coherent manner, at a precise angle
and frequency. Thus, in solid-state NMR, it is possible to defeat the
averaging of the spatial coordinates (by magic-angle spinning)
through the manipulation of the spin coordinates (by the applica-
tion of radiofrequency pulses). The REDOR measurement utilizes
the application of rotor-synchronized radiofrequency pulses to
operate exclusively on the spin coordinates and interfere with
the complete suppression of the dipolar coupling by magic-angle
spinning.1 This recoupling, or reintroduction of the dipolar cou-
pling, is the basic principle for other homonuclear recoupling tech-
niques that are also used to measure dipolar couplings and obtain
distance parameters.11–13
The REDORmeasurement: In practice, the REDORmeasurement is
performed in two parts (Fig. 1, left), once without and once with ro-
tor-synchronized dephasing pulses, yielding the full echo (S0) spec-
trum and the dephased (S) spectrum, respectively. Maximum
intensity rotational echoes are formed at the end of each rotor per-
iodwhen no dephasing pulses are applied (S0 spectrum). During the
second half of the measurement, rotor-synchronized p pulses are
applied to the dephasing spin to ﬂip the sign of the dipolar coupling,
yielding an average precessional frequency, xD (a, b; t) for each
coupled spin in the powder.1 The pulses coincident with the rotor
period serve to add the dephasing of subsequent rotor periods.Figure 1. The REDOR measurement. REDOR is performed in two parts, once with dephasi
typically collected with standard xy-8 phase cycling,55 on both observed and dephasingThe time for which the dipolar coupling operates in the REDOR
measurement is termed the dipolar evolution time (Nrtr). Each
spin accumulates a net phase due to dipolar transitions during this
time, as deﬁned in expression 2:
D/ ¼ xDða;b; t1ÞtrNf ; ð2Þ
where Du is the accumulation of phase; tr is the time of one rotor
period; Nr is the number of rotor cycles; xD is the average preces-
sional frequency for each coupled spin; a and b are the azimuthal
and polar angles, respectively, in a coordinate system with the z-
axis parallel to the rotor axis; t1 is the time of application of the p
pulse from the start of the rotor period. xD is in cycles per second,
thus multiplying xD by trNr yields a phase.
Thus, dipolar couplings result in signal attenuation at the end of
every rotor period when dephasing pulses are applied. The differ-
ence in signal intensity (DS = S0  S) for the observed spin in the
two parts of the REDOR experiment is compared to the full-echo
reference spectrum, S0, for each REDOR evolution time. Weak cou-
plings can be ampliﬁed by increasing the number of rotor cycles
(Nr) over which the dephasing occurs or by decreasing the spinning
speed (tr). Figure 2 provides the strength of the dipolar coupling
between pairs of nuclei at different distances and indicates the per-
cent dephasing (DS/S0) that would be expected in REDOR experi-
ments as a function of evolution time for 2, 4, 6, and 10 Å
distances between isolated spin pairs. Full plots of the dipolar evo-
lution for C–F, C–P, C–D, and C–N pairs at 6 Å are also illustrated.
Numerical simulations can be used to generate dephasing curves
that correspond to distributions of distances,14 or for dipolar cou-
plings in the presence of motion,15 that can be compared to the
experimental data. In terms of nomenclature, we employ the
Schaefer convention of identifying the observe and dephase spins
for a speciﬁc measurement as 13C{19F}REDOR, for example, in a car-
bon-observed ﬂuorine-dephased REDOR experiment.
Naturally, an understanding of the REDOR pulse sequence and
measurement is crucial to designing and implementing REDOR
experiments. Yet, equally important is the selection and imple-
mentation of the appropriate isotopic labeling strategy to intro-
duce pairs or clusters of labeled nuclei into the system of
interest. Many creative and highly selective isotopic labeling strat-
egies have been reported across all realms of NMR, both in solution
and solids, and only a few will be described here in the context of
the examples below. Some universal considerations include (1) the
gyromagnetic ratio of the nuclei (Fig. 1) since the dipolar coupling
to be measured scales with the c of each nucleus. As seen in Fig-
ure 2, larger couplings exhibit larger dephasing (DS/S0) in REDOR
spectra and, thus, are easier to determine accurately. In addition,
the c of the observe nucleus is important, as (2) the sensitivity of
the NMR measurement is a function of c. One must also consider
(3) the natural abundance background of the target isotope label,
whether as an observe spin or a dephasing spin, and the extentng pulses (S spectrum) and once without (full echo, S0 spectrum). REDOR spectra are
channels.
Figure 2. Dipolar couplings to distances. Strengths of the dipolar couplings (D) between pairs of nuclei at different distances and the percent dephasing (DS/S0) that would be
expected in REDOR experiments as a function of evolution time to for 2, 4, 6, and 10 Å distances between isolated spin pairs (top). Values of constants used in calculations of D
(middle). Calculated plots of DS/S0 for C–F, C–P, C–D, and C–N pairs at 6 Å for 25 ms of dipolar evolution time (bottom).
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labels or the natural abundance background or whether NMR strat-
egies to achieve selectivity are desired, such as selecting only car-
bons that are bonded to a nitrogen (as in protein carbonyls and
alpha carbons) or in proximity to phosphorous (as in lipid phos-
phate head groups). 19F is often a desired nucleus to include in a
REDOR approach to access long-range distances due to its large c,
close to that of 1H. However, it is generally used as a dephaser in
REDOR experiments. From experience with ﬂuorinated analogs of
taxol and oritavancin, as described further in this digest, the chem-
ical shift anisotropy of 19F is large and yields numerous spinning
sidebands in 19F observe spectra. In addition, the 19F isotropic shift
is very sensitive to external shielding effects,16,17 including solvent
molecules and local conformations, which results in substantial
broadening. 19F is often generally included individually at only
one or very few places in a sample in REDOR approaches and, thus,
serves well as a speciﬁc dephaser. Although possible and poten-
tially appropriate for a certain system, one could instead observe
19F, as in a 19F{13C} REDOR experiment. However, this would re-
quire frequency-selective dephasing pulses to select one carbon
type of interest, for example, and would still involve multiple car-
bon dephasers in a typical biological application. Overall, the three
examples selected to highlight the REDOR approach in this digest
include examples which involved challenging synthetic chemistry
in order to introduce isotope labels where they would provide the
most valuable information as probes of structure as well as new
biosynthetic strategies to achieve selective labeling of whole-cell
systems, together with distinct spectroscopic challenges and
considerations.Bio-active bound ligand conformations: Microtubule-bound taxol:
The determination of target-bound drug conformations is crucial
to understanding drug modes of action and to driving the design
of newmolecules with altered properties, including but not limited
to: (i) increased potency, (ii) enhanced selectivity, and (iii) reduced
toxicity. In systems inaccessible to X-ray crystallography and solu-
tion-state NMR techniques, or in systems where such information
is available but new information in the biologically relevant con-
text of a large multi-protein assembly or membrane or the whole
cell is desired, REDOR provides an avenue to determine drug-
bound conformations as well to examine proximities between
the drug and its target.
The determination of the bio-active bound conformation of the
microtubule-bound anticancer drug taxol (also known as paclit-
axel) was sought after in order to understand its structure-based
ability to bind to tubulin and to guide the development of im-
proved and perhaps simpliﬁed analogs.18 Taxol has a relatively ri-
gid central tetracyclic ring system, but has four ﬂexible side chains
that could be accommodated in numerous conformations.
Although the structure of the ab-tubulin dimer, prepared as tax-
ol-stabilized Zn-induced polymerized sheets, had been solved by
electron crystallography in 2001 and the binding site of taxol could
be identiﬁed, the 3.7 Å resolution was too low to permit the
determination of the taxol conformation. Thus, several REDOR
measurements were designed and employed to determine the con-
formation of taxol bound to intact microtubules. The latter of two
major studies18,19 determined distances between synthetically
incorporated 2H and 19F labels in taxol using 2H{19F} REDOR.18 This
selection of labels is attractive in having no natural abundance
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whereas 13C and 15N are present at natural abundance as 1.11%
and 0.37%, respectively. In the former REDOR study, using a 13C-
carbonyl labeled taxol, installation of an 15N adjacent to the 13C
in taxol was required in order to select the taxol 13C from among
the much larger 13C contributions from the natural abundance car-
bonyls in the microtubules, as there is only one taxol bound per
tubulin dimer (100 kDa).19 Deuterium, however, is quadrupolar
and has a large chemical shift anisotropy. Thus, by way of detail,
processing of 2H-observe REDOR experiments is aided by synchro-
nous sampling where the spinning sideband intensities are folded
into the centerband.20,21 The choice of 19F as one of the labels is
attractive since 19F has a c that is almost as high as 1H and, thus,
enables longer distance measurements than is possible when
selecting nuclei with lower values of c. This REDOR example also
represents one of the experimentally toughest set of distance mea-
surements reported due to the very long accumulation time neces-
sary to obtain high-quality spectra to permit the quantiﬁcation of
5% dephasing while observing the low-sensitivity 2H nucleus
(2Hc = 1Hc/6.5).
Strategically targeted 2H–19F distances were measured on two
labeled analogues, named here according to their original designa-
tion as analogues 4 (Fig. 3A) and 5 (Fig. 3B).18 Analogue 4 had a sin-
gle 19F to be used as the dephaser and two types of deuterons that
would be observed and would be shift-resolved from one another,
thus allowing the REDOR experiment to report on two sets of dis-
tances in the same experiment (Fig. 3A). The 2H3–19F distance in
analogue 4 was determined to be 7.8 ± 0.5 Å, based on the ob-
served dephasing of 8%, that is, a difference between the full-echo
(S0) and dephased spectrum (S) of 8% (Fig. 3). The single aromatic
deuterium did not exhibit signiﬁcant dephasing by the 19F and thus
a distance was not obtained for that 2H–19F pair (Fig. 3A). However,
this provided key information as one of the possible taxol models
under consideration would have resulted in a 2H–19F distance of
4.5 Å. This close proximity would have been accompanied by
100% dephasing after 8 ms of dipolar evolution time—64 rotor cy-
cles  0.125 ms, where 0.125 ms is the rotor period corresponding
to 8 kHz MAS. Thus, this REDOR result demonstrated that the
2H–19F distance must be greater than 8 Å, an important parameter
in the ﬁnal modeling. The 2H3–19F distance in analogue 5 was
determined to be 6.3 ± 0.5 Å, corresponding to approximately 6%
dephasing (Fig. 3B). The error bars in the distances resulted fromFigure 3. A 7.8 Å 2H–19F distance in taxol. (A) 2H{19F} 64-Tr REDOR spectra of tubulin-b
8 kHz, resulted in 8% dephasing and a calculated distance of 7.8 (±0.5) Å. The full-echo spe
were detected synchronously with the rotor so that all sidebands have been folded into
appears about 5 ppm to low ﬁeld. Each spectrum resulted from the accumulation of 640,
for the DS spectrum). (B) 2H{19F} 32-Tr REDOR spectra of tubulin-bound taxol analogue
dephasing and a calculated distance of 6.3 (±0.5) Å. Each spectrum resulted from the accu
Spectra were obtained on a 500 MHz spectrometer. Figure adapted from Paik et al.18the consideration of the integrals of the peak heights compared
to the integrals of an equivalent frequency width of noise.18
2H{19F} REDOR NMR provided these key distances that were able
to rule out certain conformational models that had been proposed
and support a T-shaped conformation when it is bound to tubulin
(Fig. 3).18 It was based on these collective distances that Ojima and
co-workers designed and synthesized a structurally restrained
analogue to enforce the ‘REDOR-taxol’ conformation that was as
potent as taxol, emphasizing the power in the structure-based drug
design approach.22,23 The generation of potent analogues, for can-
cer therapy as well as other indications, is invaluable towards the
identiﬁcation of compounds with improved efﬁcacy, reduced tox-
icity, and the ability to evade resistance mechanisms.
In terms of sensitivity, for typical REDOR experiments per-
formed at moderate ﬁeld strengths (300–600 MHz) in complex
biosolids, one typically aims to prepare samples which have at
least one micromole of labeled pairs. For samples such as these
noncrystalline taxol-bound microtubules as well as other assem-
blies and whole cell samples with heterogeneity, typical carbon
line widths range from 1–2 ppm up to 5 ppm. This is in contrast
to solid-state NMR studies on microcrystalline proteins, where
much less sample is required due to narrower line widths, on the
order of 0.1 ppm. Microtubules, in particular, are comprised of
the 100 kDa ab-tubulin dimers, with one taxol binding to each di-
mer. Thus, with one site of interest among the 100 kDa dimer,
1 lmol corresponds to 100 mg microtubules complexed to taxol
in a one-to-one ratio. Although some complexes contained nearly
this much material, the experiments with taxol analogue 5 con-
tained only 0.1 lmol of microtubule-bound drug. The one million
scan experiment in Figure 3 required 36 days of spectrometer time
(one million scans (18 days) for the full-echo S0 spectrum and one
million scans for the dephased S spectrum).18 In this study, a con-
trol experiment was also performed on a sample without 19F to
additionally demonstrate that the spectrometer and the probe,
which is designed with superb isolation of the 1H and 19F channels
and to permit stable long-term signal averaging, would yield per-
fectly equal S0 and S spectra in the absence of the 19F dephaser in
a one million scan experiment. The reader should note that with
just twice as much sample, the million-scan experiment would
have taken four times less time. Ideally, one wants to measure
more than one point on a REDOR curve, but as demonstrated in
the taxol example, even one point can provide crucial informationound taxol analogue 4, corresponding to 8 ms dipolar evolution time with MAS at
ctrum is shown in blue, and the dephased spectrum in red. The time domain signals
the center bands. The CD3 peak is assigned zero frequency and the aromatic-D peak
000 scans with a 1.5 s recycle delay (approximately 11 days each and, thus, 22 days
5, corresponding to 4 ms dipolar evolution time with MAS at 8 kHz, resulted in 6%
mulation of 1,056,000 scans (18 days each and, thus, 36 days for the DS spectrum).
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large samples, balancing the amount of protein or complex with
the amount of lyophilization buffer to protect the complex in the
lyophilized solid state. While some studies have involved REDOR
experiments on hydrated samples, most of the complex biological
systems we have worked with, including whole cells, and antimi-
crobial peptide–lipid vesicle complexes examined by Schaefer
and co-workers, have not yielded enhancements in resolution
due to hydration and, rather, exhibited reduced signal intensity,
making lyophilized samples more amenable to extensive REDOR
measurements.24–26 Lyophilization conditions for each sample
must be determined or optimized towards maintaining native
state conformations. In the case of taxol-bound microtubules, elec-
tron microscopy was performed to assess microtubules. Without
adequate stabilization with lyoprotectants, microtubules were of
disparate lengths; thus, buffer components were varied to achieve
preparations that were identical pre- and post-lyophilization and
which minimized buffer volume in the ﬁnal sample (unpublished
data). For other proteins and enzymes, drug-binding or activity as-
says can be implemented on samples pre- and post-lyophilization,
whereas whole-cell samples can be assayed for viability.
Targeting bacterial cell-wall assembly: REDOR has emerged as a
powerful tool to determine chemical composition, including the
quantiﬁcation of cross-links and various bond densities in complex
systems, including insect cuticle, mussel byssus, plant cells, and
bacterial cell walls.27–31 This approach has found tremendous va-
lue in the determination of the modes of action of antibiotics that
target cell-wall assembly. Such quantitative determinations pose a
challenge to analysis by conventional methods due to the insolu-
bility of the bacterial cell wall. The major component of the Staph-
ylococcus aureus cell wall is peptidoglycan, consisting of polymers
of a repeating motif consisting of a disaccharide with a pentapep-
tide stem with a pentaglycine bridge attached to the sidechain of
lysine, the third residue in the stem (Fig. 4A). Different types of
linkages exist in other Gram-positive and Gram-negative organ-Figure 4. Distances between an antibiotic and the bacterial cell wall. (A) Chemical schem
sites that are often targeted in REDOR experiments through the use of selective D-[1-13C]A
13C{19F} REDOR dephasing (DS/S0) as a function of the dipolar evolution time, t, for comple
on media containing D-[1-13C]alanine. The binding site occupancy of [19F]oritavancin co
2 lmol antibiotic was bound to 20 or 40 mg, respectively, of isolated peptidoglycan
distribution of distances for isolated 13C–19F pairs centered at 7.6 Å with a width of 1.5 Å.
500 MHz spectrometer. Figure adapted from Kim et al.35isms. In S. aureus, the intact peptidoglycan precursor is synthesized
inside the cell and transported to the membrane exoface where it
is then polymerized through the action of transglycosylation (to
link the glycans) and transpeptidation (to crosslink the glycine of
one stem with the penultimate D-Ala of a neighboring stem). Major
solid-state NMR efforts to dissect S. aureus cell-wall composition
and structure and to understand the structure-based inﬂuence of
antibiotics (with an emphasis on vancomycin and potent vanco-
mycin analogues) began in the Schaefer laboratory and are now
continuing pursuits in our laboratories and also in others. Selected
results from these studies will be described to articulate how RE-
DOR approaches, relying on unique isotopic labeling strategies
and NMR selection, can yield key atomic-level distances and quan-
titative parameters of chemical composition in both isolated cell
walls and intact whole cells.
The earliest structural studies described the structural interac-
tions of the peptidoglycan with oritavancin, a vancomycin ana-
logue that has been in clinical development (Fig. 4B).32,33 REDOR
measurements were performed using the ﬂuorinated version of
the drug, [19F]oritavancin (where replacement of the drug’s Cl with
F has no inﬂuence on activity), also known as LY329332. Figure 4C
provides REDOR data points and simulated dephasing plots corre-
sponding to the measurements of the dipolar coupling between the
drug and D-Ala in isolated S. aureus cell walls.33 Quantiﬁcation of
this distance resulted from two parameters: knowledge of the
amount of cell wall material and the percent occupancy of the drug
determined in binding assays. In particular, 2 lmol LY329332 was
bound to 20 mg of cell walls (about 12 lmol of peptidoglycan
stems) and corresponds to 33% binding site occupancy. The REDOR
experiments were performed on two samples in which the binding
occupancy was either 33% or 16%. An accounting of the contribu-
tions to the S0 spectra and an analysis of how many 13C–19F pairs
are present are central aspects of quantiﬁcation in REDOR experi-
ments such as this. In this regard, the dephasing plateau harbors
important information. For isolated 13C–19F pairs, with 33%atic of the S. aureus peptidoglycan, highlighting the unique bridge-link and crosslink
la, [15N]Gly, and L-[e-15N]Lys labeling. (B) Chemical structure of [19F]oritavancin. (C)
xes of [19F]oritavancin with peptidoglycan isolated from S. aureuswhole cells grown
mplexed to cell walls was either 33% (open circles) or 16% (closed circles), wherein
(dry mass). The calculated cell wall dephasing (solid lines) assumed a Gaussian
The dashed line also provides a reasonable ﬁt to the data. Spectra were obtained on a
5772 L. Cegelski / Bioorg. Med. Chem. Lett. 23 (2013) 5767–5775occupancy, one would start the analysis by expecting a dephasing
plateau of 33% if all carbons were coupled to a 19F. However, the
dephasing reached a plateau of 8%. In this case, a factor of about
2 was attributed to the determination that half of the peptidogly-
can stems represented actual binding sites (harboring D-Ala–D-Ala
stem termini rather than the shorter D-Ala termini) and another
factor of 2 to the coupling of each 19F to two carbons (the L-Ala
and D-Ala of a neighboring stem), yielding the reduced plateau of
8%. In these early studies, both L-Ala and D-Ala were labeled due
to alanine racemization, whereas a racemase inhibitor was used
in all subsequent studies which conﬁrm and extend this early
work.34 This early example emphasizes the need to dissect and ac-
count for labeling patterns and efﬁciencies due to in vivo biosyn-
thesis in REDOR studies in complex biosystems. The second
sample with 16% binding occupancy accordingly reached a plateau
of 4%, one-half that of the ﬁrst sample (Fig. 4C). Thus, by scaling the
dephasing based on the plateau, the data were ﬁt to a distance
centered at 7.6 Å with a width of 1.5 Å. More recent work in more
selectively labeled samples has demonstrated that oritavancinFigure 5. Site-speciﬁc antibiotic-cell wall distances in whole cells. (A) Full echo 13C CPM
media containing D-[1-13C ]Ala and [15N]Gly in the presence of an alanine racemase inhib
result of 256 scans. The TEDOR-selected 13C spectrum (top) was the result of 120,000 sca
are bonded to 15N. (B) 15N? 13C{19F} TEDOR-selected REDOR spectra of the whole-cell
cycles with MAS at 6250 Hz). S0 and S spectra resulted from the accumulation of 120,000
dipolar evolution time. The calculated dephasing using a Gaussian distribution of dist
dephasing than a single 7.0 Å distance (dashed line). The dotted lines show the calcula
obtained on a 500 MHz spectrometer. (D) Molecular model of [19F]oritavancin bound
including the featured TEDOR–REDOR distance. Figure adapted from Cegelski et al.37binding in S. aureus is homogenous and exhibits a single compara-
ble distance.34 Other REDORmeasurements indicated that the ﬂuo-
rine on [19F]oritavancin was placed co-linearly along the glycine
bridge.35 That is, it was closest to one glycine with each other gly-
cine subsequently farther away, rather than possible placement
near the middle of the bridge.35 In the latter case, the REDOR mea-
surements would have revealed one close distance and sets of
nearest distances rather than the clear arrangement of ﬁve carbons
each successively more distant than the previous one. Collectively,
these REDOR measurements determined that [19F]oritavancin
binds to a secondary peptidoglycan binding site, hugging the pen-
taglycine bridge, and explains the ability of analogues with abro-
gated primary binding sites (binding the D-Ala–D-Ala terminus)
to still bind to the cell wall and prevent cell-wall assembly,36 as
well as its activity against S. aureus with altered D-Ala–D-Lac ter-
mini (see Fig. 5D). It is crucial that these types of measurements
regarding antibiotic–cell wall complexes are made within the con-
text of native cell walls rather than synthetic cell-wall mimics as
the intact cell wall contains compact glycine bridges, for example,AS and TEDOR selected spectrum of lyophilized whole cells of S. aureus grown on
itor to ensure selective alanine labeling. The 13C CPMAS spectrum (bottom) was the
ns and harbors contributions only from labeled and natural abundance carbons that
sample complexed to [19F]oritavancin after 15 ms dipolar evolution time (96 rotor
scans. (C) 15N? 13C{19F} TEDOR-selected REDOR dephasing (DS/S0) as a function of
ances centered at 7.4 Å (solid line) provided a better match to the experimental
ted dephasing for single distances of 6.5 Å (upper) and 7.5 Å (lower). Spectra were
to the peptidoglycan of S. aureus generated from several distance measurements
Figure 6. Crosslink density and inhibition of crosslinking in whole cells. REDOR
selection and quantiﬁcation of peptidoglycan crosslinks in S. aureus whole cells
labeled with [15N]glycine and D-[1-13C]alanine and a racemase inhibitor in the
absence (black) and presence of 0.15 lg/mL penicillin (blue) and 20 lg/mL
oritavancin (green). The REDOR difference measures the relative number of cross-
links per pentagycyl bridging segment. Penicillin has a large effect, as a known
crosslinking inhibitor and oritavancin also inhibited transpeptidation. Spectra were
obtained on a 300 MHz spectrometer. Figure adapted from Kim et al.39
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soluble mimics amenable to solution-state NMR and other
methods. A comprehensive recent publication by Kim, Schaefer,
and co-workers has examined the locations of the hydrophobic
side chain of several important lipoglycopeptide analogues bound
to the cell wall to correlate structure with function.34 This work
also employed 31P{19F}REDOR to demonstrate, with other support-
ing data, that the hydrophobic side chain is not embedded in the
membrane indicating that at therapeutic-dosage levels, the side
chain does not act as a membrane anchor.34
A whole-cell strategy was also developed to characterize
[19F]oritavancin binding directly in intact whole cells.37 Prior to
these experiments, REDOR analysis from whole-cell samples re-
quired using a cell-wall S0 spectrum in order to normalize the
whole-cell S0 spectrum to distinguish the cell-wall contributions
from those of the cytoplasmic constituents.35 In the study de-
scribed here, the ﬁrst use of TEDOR–REDOR in whole cells enabled
the site-speciﬁc selection of the cross-linked D-Ala carbonyl carbon
(proposed to be near to the 19F of the drug as described above) and
subsequent distance measurement to the ﬂuorine.37 Figure 5 illus-
trates the ability to use a TEDOR (transferred-echo double-
resonance)38 transfer to ﬁrst select the 13C nuclei that are directly
bonded to 15N in cells that were biosynthetically labeled with
D-[1-13C]Ala and [15N]Gly. In the TEDOR–REDOR experiment,
the TEDOR-selected carbons (Fig. 5A) were then dephased by
19F (Fig. 5B) to measure the selected 13C–19F distance. One set of
REDOR spectra, corresponding to 15 ms evolution time, is shown
in Figure 5B and resulted from 120,000 scans, thus requiring about
4 days of acquisition. The data from ﬁve REDOR evolution times
and simulated plots demonstrated close agreement with the earlier
measurements, indicating that the C–F pairs could be ﬁt best by a
distribution of distances centered at 7.4 Å and a width of 1.6 Å
(Fig. 5C). In the case of whole cells, it was determined that there
is heterogeneity in the binding sites in the cell wall, perhaps with
slightly different conformations among layers close to the cell
membrane and those towards the outer edges of the cell wall.
The resulting model consistent with several distance measure-
ments between [19F]oritavancin and labeled peptidoglycan in S.
aureus whole-cell and cell walls is provided in Figure 5D.
In the spirit of the above strategy, one could also observe 15N and
select just the [15N]glycines that are directly bonded to the
D-[1-13C]Ala. In fact, this approach was employed as a whole-cell
NMR assay to determine whether an antibiotic can block crosslink
formation without the need to isolate cell walls or to perform per-
turbative hydrolysis measures associated with HPLC and mass
spectrometry-based proﬁling. In this example, the full-echo 15N
spectrum harbors contributions from all glycines in the cell wall
and cytoplasm and any metabolic products that resulted from
transformations of labeled glycine (Fig. 6). The REDOR difference
spectrum, DS, reveals only nitrogens that are dephased by
D-[13C]Ala, that is, crosslink sites in the cell wall. Penicillin is known
to prevent crosslink formation and, as anticipated, a clear decrease
in 13C–15N bond density was observed for cells after treatment with
penicillin.39 Thus, again, bond selectivity can be achieved in the
context of intact cells. This result demonstrated that oritavancin
can prevent crosslink formation and supported the full analysis that
oritavancin exhibits a dual mode of action in S. aureus, preventing
both transglycosylation and transpeptidation.39
Membrane-associated proximities: REDOR has also been imple-
mented to examine the structures of membrane proteins and the
interactions of proteins, peptides, and other molecules, in and
within membrane systems.25,40–51 Solid-state NMR, in general,
has been invaluable in examining the structures of membrane pro-
teins in native membrane environments. This ﬁnal section high-
lights the ability to employ 13C{31P} REDOR and 13C{19F} REDOR
to examine the relative proximities of guest molecules to lipidhead groups and lipid tails within a membrane system, particularly
utilizing the comparative power of internal lipid rulers of
reference.
In the selected example, a series of comparative REDOR mea-
surements were performed in order to map the orientation and
depth of a panel of estradiol analogues in DPPC lipid vesicles.41
The placement of the analogues correlated with their neuroprotec-
tive potency and provided support for the possibility that the more
potent analogues confer enhanced protection against oxidation of
unsaturated fatty acids in membrane lipids. The 13C{31P} REDOR
full-echo spectra in Figure 7 include all carbon contributions in
the system. Each sterol 13C label is readily resolved from the lipid
carbons. The observed dephasing (DS/S0) reveals the relative prox-
imity of each carbon type to phosphorous. As expected, the carbon-
yls of the lipid head groups exhibit strong dephasing, whereas no
13C{31P} dephasing is observed for the lipid tail methyl groups. If,
however, the membrane was perturbed, and kinks were formed,
then some lipid tails would exhibit dephasing due to their in-
creased proximity to the phosphate head groups. This can occur,
for example, when a high percentage of lipids with ﬂuorinated tails
are employed in the sample preparation.52 For this reason, prepa-
rations of this type restrict the percentage of ﬂuorinated lipids to
less than or equal to 5% of the total lipid content.
The dephasing of two different 13C-labeled versions of the same
sterol, [3-13C]estradiol benzoate and [1-13C]estradiol benzoate,
were compared to map the molecular orientation of the compound
in the bilayer. As seen in Figure 7A, it could immediately be deter-
mined that the sterol was situated with its phenolic group near to
the headgroups and the benzoate group within the bilayer. In par-
ticular, the [3-13C]estradiol benzoate label exhibited stronger 31P
dephasing than the lipid head group carbonyls and, thus, was
determined to be relatively closer to the phosphate head group
than the lipid carbonyls. Additional 13C{19F} REDOR conﬁrmed
the proximity of the benzoate group on the other side of the mol-
ecule to ﬂuorinated lipid tails (Fig. 7B). In contrast to the 13C{31P}
REDOR spectra to assess headgroup proximity, the lipid methyl
carbons and methylenes near to the tails exhibited signiﬁcant
dephasing to 19F, whereas dephasing of the head group carbonyls
was not observed due to their long distance from the ﬂuorinated
tails. In the case of potential kinking (or interdigitation and
shrinking of bilayer thickness), as mentioned above, one would ob-
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always show the full width of the REDOR spectra in such studies so
that the dephasing of the guest molecule and its proximity to cer-
tain lipid moeities can be evaluated with respect to proximities of
the internal lipid landmarks and the lipid-centric dephasing.41 This
analysis could similarly be performed to evaluate the relative prox-
imity of labels in membrane proteins or other membrane-associ-
ated components with lipid atoms. Furthermore, the
incorporation of guest molecules or proteins may even alter lipid
packing or thickness and the lipid-centric REDOR dephasing can
be compared among samples with and without additional compo-
nents. In the above study, a lipid-to-compound ratio of 20:1 was
used as employed previously in studies using antimicrobial pep-
tides.25,26 This ratio would need to be evaluated and optimized in
cases of membrane proteins or ion channels, where protein activity
can be assayed as a function of composition. REDORmeasurements
designed to access proximities to the phosphate head groups could
also be performed in intact cells or membrane extracts if there was
sufﬁcient resolution of the desired carbon resonance(s) from the
natural abundance background in the cellular system, or if the
guest molecule was labeled with 19F or 2H. However, in the context
of whole cells, one would not immediately beneﬁt from the use of
the internal lipid landmarks since carbonyl contributions in the
S0 spectrum, for example, would harbor all proteins and
carboxyl-group containing molecules. Nevertheless, as shown in
work with the antibiotic, oritavancin, lack of REDOR dephasing be-
tween 19F (incorporated in the antibiotic) and 31P in whole cell
preparations of S. aureus with the antibiotic added at therapeuti-
cally relevant concentrations, revealed that the hydrophobic sub-
stituent on the antibiotic was not near to lipid headgroups, that
is, membrane anchors were not detected.34 Thus, the lack of
dephasing yielded important insight in the context of a relevant,
whole-cell system.
Conclusions and outlook: REDOR is a versatile tool in the drug
discovery toolbox. Looking towards the future, challenges exist in
examining large membrane proteins, such as G-protein coupled
receptors (GPCRs), yet nearly half of all clinically available drugs
target GPCRs. While pioneering crystallography and NMR efforts
have delivered tremendous structural insights into the b-adrener-Figure 7. Lipid cartography and guest-lipid proximities. (A) 13C{31P} REDOR spectra
[3-13C]estradiol benzoate (left) and estradiol [1-13C]benzoate (right) after 9 ms of dipola
estradiol [1-13C]benzoate-containing vesicles. The substantial dephasing for the label i
obtained on a 500 MHz spectrometer. Figure adapted from Cegelski et al.41gic receptor53 and other important ion transporters and membrane
proteins, the structures open up many additional and important
avenues of study needed to further understand structure–function
relationships, particularly in membrane environments, and the
modes of action of molecular inhibitors. A challenge for REDOR
in these systems is the need for adequate amounts of sample, as
emphasized in the examples above. These examples were not
microcrystalline proteins or assemblies that yield extremely nar-
row lines, thus more signal averaging and/or sample was required
to obtain high-resolution spectra than on proteins which exhibit
extremely high order or crystallinity. Yet, the taxol example illus-
trates the extent to which one can push the envelope on achieving
a balance between sensitivity and the selection of the REDOR mea-
surement to deliver key distances needed to solve crucial problems
in drug design. Indeed, the ability to implement REDOR and report
directly on the conformation of particularly large natural product
molecules, such as taxol, is imperative to driving efforts to re-de-
sign and re-engineer the architecture of complex molecules, poten-
tially simplifying synthetic efforts and enabling the discovery and
generation of new analogues. In addition, advancements in dy-
namic nuclear polarization (DNP) should also enable the extension
of REDOR to sample- and sensitivity-limited studies.
Enormous efforts are also underway to map the human kinome
and to identify inhibitors of kinases that are also integral to signal
transduction cascades. Even when crystal structures of proteins
and protein–inhibitor complexes exist, there are sometimes ques-
tions as to whether crystallization alters the conformation or re-
duces inherent heterogeneity to a single population. Dynamics
may also play a role in drug binding and, in addition to other
NMR dynamics measurements, REDOR can be integrated with
experiments like CODEX54 to map selected structural changes with
dynamics. Similarly, as also discussed, there is an ever-increasing
need for new strategies to prevent and treat infectious diseases
due to the dwindling number of candidate antibiotics in the drug
development pipeline and the continued and inevitable emergence
of bacterial strains resistant to current antibiotics. For antibiotic
candidates that interact with the cell wall and inﬂuence cell-wall
assembly, REDOR is uniquely suited to examine drug modes of
action in intact and insoluble samples, whereas most otherof multilamellar vesicles containing 5% ﬂuorinated DPPC and 95% DPPC with
r evolution (64 Tr with MAS at 7143 Hz). (B) 13C{19F} 128-Tr REDOR spectra of the
n the benzoate ring placed that carbon proximate to the lipid tails. Spectra were
L. Cegelski / Bioorg. Med. Chem. Lett. 23 (2013) 5767–5775 5775methods rely on degradation of the cell-wall or the use of cell-wall
surrogates that do not capture the structure and architecture of the
intact cell wall. In summary, REDOR has emerged as a key prob-
lem-solving tool in the structural biology and biochemical toolbox
and is needed to address outstanding problems in biology and
medicine. The future is extremely bright for new REDOR
approaches to deliver exciting discoveries to drive the design and
development of new therapeutics.
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